TargetMol

Ganetespib

Product Code:
 
TAR-T2309
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2309-5mg5mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-1mL1 mL * 10 mM (in DMSO)£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-10mg10mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-25mg25mg£179.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-50mg50mg£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-100mg100mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-200mg200mg£429.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2309-500mg500mg£664.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ganetespib is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.
CAS:
888216-25-9
Formula:
C20H20N4O3
Molecular Weight:
364.405
Pathway:
Metabolism; Apoptosis; Cytoskeletal Signaling
Purity:
0.9995
SMILES:
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O
Target:
Apoptosis; HSP

References

1. McCleese Jk, et al. Int J Cancer. 2009, 125(12), 2792-2801. 2. Wang Y, et al. Curr Opin Investig Drugs. 2010 , 11(12), 1466-1476. 3. Ying W, et al. Mol Cancer Ther. 2012, 11(2), 475-484. 4. Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277. 5. Peng Y C, Wang S, Zhang Y, et al. Hsp90? inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy[J]. Journal of Asian natural products research. 2018 Nov 17:1-11.